Mainstay Capital Management LLC Acadia Pharmaceuticals Inc Transaction History

Mainstay Capital Management LLC

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2022 Aug 05, 2022	SELL	$13.01 - $27.22 $340,081 - $711,530	-26,140 Closed	0 $0
Q1 2022 May 10, 2022	BUY	$20.94 - $27.5 $3,832 - $5,032	183 Added 0.71%	26,140 $633,000
Q4 2021 Feb 15, 2022	SELL	$16.79 - $27.09 $101,965 - $164,517	-6,073 Reduced 18.96%	25,957 $606,000
Q3 2021 Nov 12, 2021	BUY	$15.78 - $24.77 $73,613 - $115,552	4,665 Added 17.05%	32,030 $532,000
Q2 2021 Aug 06, 2021	SELL	$19.4 - $27.42 $3,879 - $5,484	-200 Reduced 0.73%	27,365 $667,000
Q1 2021 May 13, 2021	SELL	$25.02 - $54.99 $49,789 - $109,430	-1,990 Reduced 6.73%	27,565 $711,000
Q4 2020 Mar 04, 2021	SELL	$41.04 - $56.79 $5,950 - $8,234	-145 Reduced 0.49%	29,555 $1.58 Million
Q3 2020 Nov 13, 2020	SELL	$36.42 - $57.0 $119,093 - $186,390	-3,270 Reduced 9.92%	29,700 $1.23 Million
Q2 2020 Jul 23, 2020	BUY	$39.26 - $52.73 $6,281 - $8,436	160 Added 0.49%	32,970 $1.6 Million
Q1 2020 Apr 23, 2020	SELL	$31.65 - $46.87 $29,909 - $44,292	-945 Reduced 2.8%	32,810 $1.33 Million
Q4 2019 Jan 21, 2020	BUY	$36.21 - $51.4 $1.22 Million - $1.74 Million	33,755 New	33,755 $1.44 Million

288

161M

723K

257K

Ticker ACAD
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 161,843,008
Market Cap $2.39B
Description
ACADIA Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of small molecule drugs that address unmet medical needs in central nervous system disorders. The company offers NUPLAZID (pimavanserin) for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis. It's p...

Get notified when there are updates to the investment portfolio of Mainstay Capital Management LLC , based on Form 13F filings with the SEC.

Stay updated on Mainstay Capital Management LLC with notifications on news.